The advent of ATTR-specific drugs, though pricey, is enabling better survival in these overlapping diseases, researchers say.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

A compound found in the gut may reduce some of the manifestations of Alzheimer's disease, according to a Northwestern ...

A new portable device developed by Rutgers University researchers can detect genetic mutations linked to hereditary ...

The world just got a little closer. The new iGlobal Radio App is now live, offering users a dynamic way to connect with radio ...

New analysis of traffic patterns on Toronto's Gardiner Expressway reveals a harsh reality for commuters and commercial fleets alike: ongoing construction is effectively doubling travel times in key ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

A team led by Rutgers University-New Brunswick engineers has developed a portable device capable of detecting rare genetic ...

The drug is already approved in the EU for transthyretin amyloidosis with polyneuropathy but now covers patients with cardiomyopathy.